COL3A1 and melanoma: Based on the findings of this study, prospective clinical trials should be performed to confirm the potential implications of COL3A1 mutations, mutational signature 4, the identified immune subtype, and other immunotherapy determinants in melanoma and other cancer types, which will provide more clues for guiding clinical practice and individualized treatment.